AbbVie Pushes Greater Flexibility With Oral Migraine Preventative Atogepant

With an FDA approval decision for preventing episodic migraines expected during Q3, atogepant would add an oral CGRP antagonist to classmate Ubrelvy for acute attacks and Botox for prevention of chronic episodes.

Diagnosis - Migraine. Medical Concept with Red Pills, Injections and Syringe. Selective Focus. 3D Render.
AbbVie hopes it will have a third approved migraine therapy by year's end

Atogepant, if approved, will be the third tool in AbbVie Inc.’s migraine box and the final step in building a franchise around the idea of optionality. The oral CGRP inhibitor is under US FDA review for prevention of episodic migraines, and should it reach the market will compete against a trio of established injectable antibodies. But AbbVie thinks beyond the convenience advantage of the oral option, it will be a more flexible alternative that could be easier to gain new patients.

Looking at final Phase III data presented at the American Association of Neurology annual meeting on 20 April, atogepant’s efficacy...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.